These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28167540)

  • 21. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity.
    Morris MI
    Am J Health Syst Pharm; 2009 Feb; 66(3):225-36. PubMed ID: 19179636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Refractory Hypokalemia from Syndrome of Apparent Mineralocorticoid Excess on Low-Dose Posaconazole.
    Wassermann T; Reimer EK; McKinnon M; Stock W
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661880
    [No Abstract]   [Full Text] [Related]  

  • 23. Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
    Döring M; Eikemeier M; Cabanillas Stanchi KM; Hartmann U; Ebinger M; Schwarze CP; Schulz A; Handgretinger R; Müller I
    Eur J Clin Microbiol Infect Dis; 2015 Jun; 34(6):1189-200. PubMed ID: 25680318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe acute hypokalaemia secondary to voriconazole. Uncommon pharmacological causes of hypokalaemia.
    González Rozas M; Alvarez Tundidor S; Pineda Alonso M
    Nefrologia; 2011; 31(1):112-3. PubMed ID: 21270925
    [No Abstract]   [Full Text] [Related]  

  • 25. Posaconazole prophylaxis during induction therapy of patients with acute lymphoblastic leukaemia.
    Illmer T; Babatz J; Pursche S; Stölzel F; Schuler U; Schaich M; Ehninger G
    Mycoses; 2011 Jul; 54(4):e143-7. PubMed ID: 20337942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicity of Vincristine Combined With Posaconazole in Children With Acute Lymphoblastic Leukemia.
    Pekpak E; İleri T; İnce E; Ertem M; Uysal Z
    J Pediatr Hematol Oncol; 2018 Jul; 40(5):e309-e310. PubMed ID: 29219892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world experience with posaconazole prophylaxis in high-risk hematological patients in Singapore: a prospective audit.
    Low CY; Ong WC; Wong E; Ding Y; Diong CP; Jin J; Lim ZY; Hsu LY
    J Infect; 2013 Mar; 66(3):291-4. PubMed ID: 23201153
    [No Abstract]   [Full Text] [Related]  

  • 28. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
    Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
    N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Posaconazole: new indications. Prevention of invasive mycosis and treatment of oropharyngeal candidiasis: no therapeutic advantage.
    Prescrire Int; 2008 Dec; 17(98):233. PubMed ID: 19422144
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety of posaconazole.
    Jacinto PL; Chandrasekar P
    Expert Opin Drug Saf; 2013 Mar; 12(2):265-74. PubMed ID: 23360443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Posaconazole plasma concentrations in pediatric patients receiving antifungal prophylaxis during neutropenia.
    Döring M; Cabanillas Stanchi KM; Klinker H; Eikemeier M; Feucht J; Blaeschke F; Schwarze CP; Ebinger M; Feuchtinger T; Handgretinger R; Heinz WJ
    Med Mycol; 2017 Jun; 55(4):375-384. PubMed ID: 27703016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience.
    Jeong W; Haywood P; Shanmuganathan N; Lindsay J; Urbancic K; Ananda-Rajah MR; Chen SC; Bajel A; Ritchie D; Grigg A; Seymour JF; Peleg AY; Kong DC; Slavin MA
    J Antimicrob Chemother; 2016 Dec; 71(12):3540-3547. PubMed ID: 27521358
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Posaconazole.
    Keating GM
    Drugs; 2005; 65(11):1553-67; discussion 1568-9. PubMed ID: 16033292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases.
    Müller C; Arndt M; Queckenberg C; Cornely OA; Theisohn M
    Mycoses; 2006; 49 Suppl 1():17-22. PubMed ID: 16961577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hypokalemia induced by amphotericin B].
    Edoute Y; Silbershatz I
    Harefuah; 1999 Nov; 137(10):477-80. PubMed ID: 10959350
    [No Abstract]   [Full Text] [Related]  

  • 36. Posaconazole serum level on day 2 predicts steady state posaconazole serum level.
    Green MR; Woolery JE
    Ther Drug Monit; 2012 Feb; 34(1):118-9. PubMed ID: 22249348
    [No Abstract]   [Full Text] [Related]  

  • 37. Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy.
    Chae H; Cho SY; Yu H; Cha K; Lee S; Kim M; Kim Y; Kim YJ; Kim HJ; Lee DG
    Clin Chim Acta; 2015 Oct; 450():220-6. PubMed ID: 26319883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posaconazole concentrations after allogeneic hematopoietic stem cell transplantation.
    Heinz WJ; Einsele H; Helle-Beyersdorf A; Zirkel J; Grau A; Schirmer D; Lenker U; Klinker H
    Transpl Infect Dis; 2013 Oct; 15(5):449-56. PubMed ID: 23890126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Persistent CNS toxicity in a patient receiving posaconazole tablets after discontinuation of voriconazole due to supratherapeutic serum levels.
    Foolad F; Kontoyiannis DP
    J Antimicrob Chemother; 2018 Jan; 73(1):256-258. PubMed ID: 29121264
    [No Abstract]   [Full Text] [Related]  

  • 40. Posaconazole: an extended-spectrum triazole antifungal agent.
    Schiller DS; Fung HB
    Clin Ther; 2007 Sep; 29(9):1862-86. PubMed ID: 18035188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.